| The following benefits are common to both the amino acid analysis and protein end group sequencing technologies. |
|
| Current State of technology |
Our Company’s technology |
| Slow, often requiring hours per sample. |
Rapid, seconds to minutes (can be made real-time). |
| Can only analyze one sample at a time. |
Potentially analyze thousands of samples simultaneously. |
| Insensitive, typically nanomole to picomole. |
Ultra-sensitive, picomole to femtomole (more than a thousand times more sensitive). |
| Requires technical experts to operate. |
No expert knowledge required. |
| Real-time analysis not possible. |
Real-time analysis possible. |
| No in-situ analysis possible. |
In-situ analysis possible. |
| Large instruments required. |
Can be built using microchips or optic fibers. |
| Requires complicated and sophisticated instrumentation. |
Uses simple instrumentation. |
| Requires large quantities of expensive reagents. |
Requires very small quantities of less expensive reagents. |
| Severe limitations on device designs. |
Many device designs possible, including: biosensors, microtiter plate kits, integrated microfluidic systems (Lab on a Chip). |
| Must be used in lab environments. |
Can be used anyplace, such as attached or embedded in organisms. |
| Requires derivatization of amino acids. |
No amino acid derivatization required. |
| Expensive to manufacture and ship. |
Mass produced at reasonable cost. |
· ·